Siolta Therapeutics is a clinical-stage biopharmaceutical company spun out of UCSF that develops defined-consortia live biotherapeutic products to prevent and treat diseases rooted in a disrupted microbiome. Its lead program, STMC-103H, is an oral multi-strain therapy aimed at preventing atopic diseases such as atopic dermatitis and food allergy in newborns, built on the company's proprietary Precision Symbiotics Platform.
Concerto Biosciences is a Cambridge, Massachusetts microbiome company that turns microbial ecology into health products. Its patented kChip platform screens millions of microbial interactions in nanoliter droplets to discover 'ensembles' - small, defined groups of microbes that work together to shepherd a damaged microbial community back to health. The company's lead program, ENS-002, is a topical live biotherapeutic for atopic dermatitis that suppresses Staphylococcus aureus without nuking the skin's helpful microbes. Founded in 2020 by scientists out of MIT and the Broad Institute, Concerto pairs ultra-high-throughput biology with AI to make microbial communities predictable and engineerable.
Bloom Science is a San Diego clinical-stage biotech translating the biology of the ketogenic diet into oral live biotherapeutics that act through the gut-immune-brain axis. Built on microbiome research licensed from UCLA and powered by its IrisRx discovery platform, the company is developing BL-001, a once-daily bacterial therapy being studied in obesity and in drug-resistant seizures from Dravet syndrome, with a pipeline reaching toward ALS and neurodegenerative disease.